Medicus Pharma (NASDAQ: MDCX) has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acute urinary retention (AURr) in men with benign prostatic hyperplasia (BPH) as part of its existing open Investigational New Drug for Teverelix.
According to Medicus, the Phase 2 study design has been refined under the leadership of Steven A. Kaplan, MD, FACS, a globally recognized leader in urology and men’s health, who will serve as principal investigator.
In a statement, Dr. Raza Bokhari, executive chairman and CEO of Medicus, commented, “This refined study design reflects a more capital-efficient development strategy intended to accelerate Teverelix’s path to commercialization. By focusing on clear pharmacodynamic endpoints and incorporating an interim analysis designed to inform subsequent clinical development, we believe Teverelix can generate actionable clinical data more rapidly, enabling earlier strategic engagement and potential partnering opportunities.”
